
In March 2017, a group of researchers in Vancouver, along with a colleague in Philadelphia, published a paper in the Proceedings of the National Academy of Sciences (PNAS) concluding that a particular antibiotic might be useful for treating conditions in people with rare mutations.
Then, this past July, while continuing the work, they had an unexpected result. That made them suspect that the antibiotic they thought they had ordered, gentamicin, wasn’t what they thought it was. With the help of a different company that sells the antibiotic, they confirmed they were studying a different compound — and retracted the paper.
Here’s the notice for “Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity:” Continue reading Researchers retract PNAS paper when they realize they’d been victims of an antibiotic switcheroo